Epidiolex (cannabidiol) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	MBER:			
MALE FEMALE HEIG	GHT (IN/CM): WEIGH	HT (LB/KG): ALLERGI	IES:	
IF YOU ARE NOT THE PATIENT OR THE PRESCR FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM</u>	The state of the s	OSURE AUTHORIZATION FORM WITH THIS REQ	UEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:		,		
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page



Epidiolex (cannabidiol) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

VIEWIDER 3 LAST NAIVIE: IVIEWIDER 3 FIRST NAIVIE					
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO			
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Lennox-Gastaut syndrome					
☐ Dravet syndrome					
□ Tuberous sclerosis complex(TSC)					
☐ Other diagnosis:ICD-					
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A			
Clinical Information:					
Lennox-Gastaut Syndrome:					
	east 2 anti-epileptic drugs? Yes No	Please submit documentation			
<u> </u>	zures per week while on current anti-ep				
submit documentation.	ares per week write on current until ep	meptie regiment. I res I no ricuse			
	nti-epileptic drug concomitantly with Ep	nidiolex? □ Yes □ No			
Dravet Syndrome :					
Is patient having at least four convulsi	ve seizures per 28 days while on current	t anti-epileptic regimen? 🗆 Yes 🗆 No			
Please submit documentation.					
Will patient be on at least one other a	nti-epileptic drug concomitantly with Ep	pidiolex? □ Yes □ No			
•	oses, symptoms, medications tried or fa	iled, and/or any other information the			
physician feels is important to this review?					
9 . 9	e covered on all plans. This request may	be denied unless all required			
information is received.					
	n provided is true and accurate to the bes				
· · · · · · · · · · · · · · · · · · ·	o or its designees may perform a routine	•			
information necessary to verify the acc	uracy of the information reported on thi	is form.			
Dunnauihau Cimpatuus au Flactusuis I B	Vauifiantian	Date			
Prescriber Signature or Electronic I.D.	Verification:	Date:			
	ompanying this transmission contain confidential				
	eby notified that any disclosure, copying, distribut				
of these documents is strictly prohibited. If you	have received this information in error, please no	otify the sender immediately (via return FAX)			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.